医药行业周报：预期修正，关注长期价值-20260309

Investment Rating - The report maintains a "Recommended" rating for the pharmaceutical industry [1] Core Insights - The report highlights the rapid growth of China's innovative pharmaceuticals, with 39 license-out transactions and upfront payments totaling approximately $2.953 billion, indicating a strong trend in international collaboration [2] - Despite the positive outlook for innovative drugs, the innovative drug index has declined by 4.84%, underperforming the CSI 300 index by 4.25 percentage points, suggesting a disconnect between market sentiment and fundamentals [2] - The report emphasizes the importance of clinical data validation and milestone payments in the upcoming phase for China's innovative pharmaceuticals, particularly after a period of market anticipation [2] Summary by Sections 1. Pharmaceutical Market Tracking - The pharmaceutical industry index has recently underperformed, ranking 17th among 31 primary industry indices with a decline of 2.78% [21][23] - The industry has seen a monthly decline of 3.09%, underperforming the CSI 300 index by 3.45 percentage points [24][42] 2. Supply-side Macro Background Changes - The report notes that the prices of upstream chemical products have generally increased due to various policies, with 90% of monitored products experiencing price hikes [3] - Specific raw materials like vitamins and amino acids have begun to see price increases, indicating a shift in the pricing cycle [3] 3. Dual-use Item Management - The management of dual-use items is expected to create significant price differences between domestic and international markets, potentially benefiting domestic medical products [4] 4. GLP-1 Oral Era - The report discusses the significant market share increase of GLP-1 drugs, with Eli Lilly's sales reaching $36.5 billion in 2025, and the introduction of oral GLP-1 medications expected to change the market dynamics [5] 5. Small Nucleic Acid Field - The report highlights ongoing mergers and collaborations in the small nucleic acid sector, with significant financial commitments from companies for innovative therapies [6] 6. Retail Drug Market - The retail drug market in China showed a positive trend in Q4 2025, with a total retail scale of 616.5 billion yuan, although the annual growth rate remained slightly negative at -0.57% [7] 7. Focus on Oral Immunomodulatory Drugs - The report emphasizes the potential of oral immunomodulatory drugs, particularly in treating psoriasis, with promising clinical trial results for new candidates [8] 8. Stock Recommendations - The report provides specific stock recommendations based on various trends, including raw material cycles, dual-use item management, and advancements in small nucleic acids and oral immunomodulatory drugs [10][12]